{"authors": [["Toth", "Peter P", "PP", "CGH Medical Center, Preventative Cardiology, Sterling, USA."], ["Bays", "Harold", "H", "L-MARC, Endocrinology, Diabetes and Metabolism, Louisville, USA."], ["Farnier", "Michel", "M", "Point Medical, Department of Lipidology, Dijon, France."], ["Jensen", "Erin", "E", "Merck & Co., Inc., Cardiovascular, Kenilworth, USA."], ["Tomassini", "Joanne E", "JE", "Merck & Co., Inc., Cardiovascular, Kenilworth, USA."], ["Polis", "Adam", "A", "Merck & Co., Inc., Cardiovascular, Kenilworth, USA."], ["Lin", "Jianxin", "J", "Merck & Co., Inc., Cardiovascular, Kenilworth, USA."], ["Bird", "Steve", "S", "Merck & Co., Inc., Cardiovascular, Kenilworth, USA."], ["Foody", "Joanne", "J", "Merck & Co., Inc., Cardiovascular, Kenilworth, USA."], ["Tershakovec", "Andrew M", "AM", "Merck & Co., Inc., Cardiovascular, Kenilworth, USA."]], "text": "", "id": "29365924", "date": "2017-08-12", "title": "A comparison of the attainment of guideline-recommended LDL-C lowering with statin and ezetimibe+statin therapies.", "doi": "10.1016/j.atherosclerosis.2017.06.781", "journal": ["Atherosclerosis", "Atherosclerosis"]}